



12-03-03

Docket No. 104914.231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

17513 U.S. PTO
10/726258




In re Reissue Application of : Jeffrey M. Leiden
Filing Date : Herewith
For : Long-Term Expression of Erythropoietin and Growth
Hormone by Transforming Muscle Cells

Based on U.S. Patent No. 6,613,319

Application No. : 09/091,134
Filing Date : June 23, 1998
(Continued Prosecution Application filed
December 18, 2000)
Examiner : Falk, Anne Marie
Art Unit : 1632

Mail Stop: REISSUE
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



REISSUE APPLICATION TRANSMITTAL LETTER

Sir:

Transmitted herewith is a request for the reissue of U.S. Patent No. 6,613,319 issued on September 2, 2003.

Enclosed are the following:

1. SPECIFICATION AND CLAIMS
☒ 12 pages of specification and claims

2. REISSUE APPLICATION DECLARATION BY THE ASSIGNEE

☒ 2 pages of declaration and power of attorney

3. PRELIMINARY AMENDMENT

☒ attached

4. EVIDENCE OF OWNERSHIP

In accordance with 37 C.F.R. § 1.172, this application for reissue is accompanied by

☒ Statement under 37 C.F.R. § 3.73(b)

5. LETTERS PATENT

In accordance with 37 C.F.R. § 1.178, this application for reissue is accompanied by

☒ offer to surrender by the assignee of the entire right, title and interest

☐ original letters patent attached

☐ declaration that original letters patent lost or inaccessible

6. PETITION UNDER 37 C.F.R. §§ 1.55 AND 1.78 FOR THE ACCEPTANCE OF AN UNINTENTIONALLY DELAYED CLAIM FOR PRIORITY

☒ attached

7. CLAIM FOR PRIORITY UNDER 35 U.S.C. §§ 119 AND 120


☒ Priority of International Application No. PCT/US97/14764, filed on August 22, 1997 is claimed

☒ Priority of United States Provisional Application No. 60/024,511, filed on August 23, 1996 is claimed

The Commissioner is authorized to charge the sum of \$2050.00, which represents the basic filing fee (\$750.00) and petition fee (\$1300.00) due for filing this Reissue application to our Deposit Account No. 08-0219. The Commissioner is further authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 associated with the pendency of this application except for an issue fee, or credit any overpayment to our Deposit Account No. 08-0219.

Respectfully submitted,

December 1, 2003


M. Lisa Wilson
Registration No. 34,045

HALE AND DORR LLP
300 Park Avenue
New York, NY 10022

Direct Line: (212) 937-7258
Tel: (212) 937-7200
Fax: (212) 937-7300

Email: lisa.wilson@haledorr.com